Exelixis (EXEL) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.91
- Estimate
- $0.89
- Surprise
- +2.7%
- Revenue (period 2026-07-03)
- $628.7M
- Score today
- 6.1/10
Revenue source: xbrl.
How the report landed
Exelixis (EXEL) beat the $0.89 estimate with diluted EPS of $0.91 — a modest 2.7% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates EXEL Buy (Wait) at 6.1/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +2.7% surprise compares with a +12.9% four-quarter average. Next scheduled report: 2026-10-27.
What supports the rating
- V7 flight-to-quality bonus: +0.5 (Q=9.2 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: cabozantinib
- Analyst target reached - limited upside remaining
- Near 52-week high (4.9% away)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $56.75
- Entry target
- $46.11
- Price target
- $58.53
- Stop
- $42.83
- Upside to target
- +3.1%
The stock trades at 17.7× trailing but 13.4× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-09-17 — shown for context, not personalized investment advice.
EXEL at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $14.10B
- P/E (fwd)
- 13.4
- P/E (ttm)
- 17.7
- 52-week range
- $33.76–$59.72
- Off 52-week high
- 5.0%
- RSI (14)
- 53
- Volume vs avg
- 0.91×
- Score today
- 6.1/10